Regarding GITR’s expression levels, in a study examining the role of TIM-3, a member of T-cell immunoglobulin and mucin domain family, TIM-3 positive CD4 T cells within tumor tissues from various cancer types, including hepatocellular, cervical, colorectal, and ovarian carcinomas, have shown elevated expression levels of CD25, Foxp3, CTLA-4, and GITR when compared to their TIM-3 negative CD4 T cell counterparts [87]. This evidence concerns the gene TNFRSF18 and ovarian carcinoma.